Clinical trial
Use of Activated Recombinant Human Factor VII in Cardiac Surgery
NCT00154427 · Novo Nordisk A/S, Industry · Terminated
Key facts
| NCT number | NCT00154427 |
|---|---|
| Title | Use of Activated Recombinant Human Factor VII in Cardiac Surgery |
| Official title | A Multi-centre, Randomised, Double-blind, Placebocontrolled, Dose Escalation Trial on Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Post-operative Bleeding in Patients Following Cardiac Surgery Requiring Cardiopulmonary Bypass |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass |
| Intervention type | Drug |
| Interventions | activated recombinant human factor VII |
| Enrollment | 172 |
| Start date | Aug 1, 2004 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Sep 12, 2005 |
| Last update posted | Jan 12, 2017 |
| Countries | Argentina, Brazil, Denmark, France, Germany, India, Italy, Malaysia, Singapore, South Africa, Spain, Sweden and 2 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: